• Wednesday, Oct 27, 2021
  • Last Update : 01:40 am

Gilead's remdesivir shows improvement in moderate Covid-19 patients

  • Published at 09:59 am June 2nd, 2020
FILE PHOTO: An ampule of remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (Covid-19) continues. Reuters

Around 70% of patients who received remdesivir for 10 days showed improvement

Gilead Sciences Inc on Monday reported that its antiviral drug remdesivir provided a modest benefit in patients with moderate COVID-19 given a five-day course of the treatment, while those who received the medicine for 10 days in the study did not fare as well.

Gilead shares fell about 4%.

Remdesivir, which is administered intravenously in hospital, is the first drug to show improvement in Covid-19 patients in formal clinical trials, and new information about its efficacy is being closely watched around the world, as nations battle the pandemic.

The late stage study of nearly 600 patients evaluated the safety and efficacy of five and 10-day treatment with remdesivir in addition to standard care for those with moderate Covid-19 - the disease caused by the new coronavirus - compared with standard care alone.

At day 11, around 76% of the patients in the five-day treatment group showed improvement in clinical status versus 66% for standard care alone, Gilead said.

Around 70% of the patients who received remdesivir for 10 days showed improvement, “trending toward but not reaching statistical significance,” the drugmaker said.

Further study details than Gilead provided on Monday, such as more information on patient demographics, are needed to explain the difference in the two treatment groups, doctors and analysts said.

Remdesivir is being closely watched after the US Food and Drug Administration granted emergency use authorization (EUA)last month, citing results from a US government study that showed the drug reduced hospitalization stays by 31%, or about four days, compared to a placebo.

The FDA did not immediately respond to a request for comment on whether it would consider expanding the EUA, and Gilead told Reuters it was in discussions with the regulator to determine the appropriate patients to be treated under the authorization.

There are currently no treatments with US approval or vaccines for the new coronavirus that has infected more than 6 million people and killed nearly 373,000 worldwide, including over 104,000 US deaths.

The drug has received approval by Japanese health regulators. US approval requires a rigorous, time consuming FDA review, but EUAs can be used in a health crisis when other options are not available.

Dozens of companies are working on a variety of treatment and vaccine approaches for the illness.

The drug, which previously failed as a treatment for Ebola, is designed to disable the mechanism by which certain viruses, including the new coronavirus, make copies of themselves and potentially overwhelm their host’s immune system.

Dr Daniel McQuillen, an infectious disease specialist at Lahey Hospital & Medical Center in Burlington, Massachusetts, said it was difficult to draw a conclusion on why the patients on the shorter course outperformed those on the longer one until the full data is released.

The trial results “confirm our and others’ anecdotal experience,” McQuillen said in an email. “The drug has promise in hospitalized patients treated early, when the illness is still in its viremic phase,” meaning the virus is circulating in a patient’s bloodstream.

Jefferies analyst Michael Yee said the improvements seen were only modest.

“This incrementally adds to a broader utilization of the drug into a more moderate population inside the hospital, but consensus already understands remdesivir is not a silver bullet,” Yee wrote in a research note.

Facebook 68
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail